Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

Abstract HER2+ breast cancer (BC) is an aggressive subtype genetically and biologically heterogeneous. We evaluate the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in 154 HER2+ BCs patients who received trastuzumab-based neoadjuvant...

Full description

Bibliographic Details
Main Authors:	Sandra Orrù, Emanuele Pascariello, Barbara Pes, Vincenzo Rallo, Raffaele Barbara, Marta Muntoni, Francesca Notari, Gianfranco Fancello, Cristina Mocci, Maria Rosaria Muroni, Paolo Cossu-Rocca, Andrea Angius, Maria Rosaria De Miglio
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-08-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-023-40071-2

Similar Items

Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes
by: Sandra Orrù, et al.
Published: (2022-01-01)

Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype
by: Andrea Angius, et al.
Published: (2020-11-01)

Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma
by: Maria Rosaria Muroni, et al.
Published: (2021-08-01)

A Portrait of Intratumoral Genomic and Transcriptomic Heterogeneity at Single-Cell Level in Colorectal Cancer
by: Andrea Angius, et al.
Published: (2021-11-01)

Portrait of Cancer Stem Cells on Colorectal Cancer: Molecular Biomarkers, Signaling Pathways and miRNAome
by: Andrea Angius, et al.
Published: (2021-02-01)

Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges
by: Xiaofen Wen, et al.
Published: (2023-10-01)

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
by: Paolo Cossu-Rocca, et al.
Published: (2015-01-01)

Quantitative Metabolomics to Explore the Role of Plasma Polyamines in Colorectal Cancer
by: Donatella Coradduzza, et al.
Published: (2022-12-01)

Metaproteomic Profile of the Colonic Luminal Microbiota From Patients With Colon Cancer
by: Alessandro Tanca, et al.
Published: (2022-04-01)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
by: M. C. Liefaard, et al.
Published: (2023-06-01)

Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis
by: Francesca Sanges, et al.
Published: (2020-06-01)

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
by: Mariausilia Franchina, et al.
Published: (2023-08-01)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
by: Guoshuang Shen, et al.
Published: (2021-07-01)

Antineoplastic Properties by Proapoptotic Mechanisms Induction of <i>Inula viscosa</i> and Its Sesquiterpene Lactones Tomentosin and Inuviscolide
by: Rossana Migheli, et al.
Published: (2022-10-01)

Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival
by: Duaa S. Helal, et al.
Published: (2023-02-01)

Assessing the Predictive Power of the Hemoglobin/Red Cell Distribution Width Ratio in Cancer: A Systematic Review and Future Directions
by: Donatella Coradduzza, et al.
Published: (2023-12-01)

Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01)

Antiproliferative and proapoptotic effects of extract on Burkitt lymphoma cell line
by: Patrizia Virdis, et al.
Published: (2020-02-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Therapeutic Landscapes in Colorectal Carcinoma
by: Antonio Mario Scanu, et al.
Published: (2023-04-01)

Editorial: Reviews in breast cancer
by: Maria Rosaria De Miglio, et al.
Published: (2023-05-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

On the of classification of BL Her subtype of the Type II Cepheids
by: Jurkovic Monika I.
Published: (2015-01-01)

Tomentosin a Sesquiterpene Lactone Induces Antiproliferative and Proapoptotic Effects in Human Burkitt Lymphoma by Deregulation of Anti- and Pro-Apoptotic Genes
by: Patrizia Virdis, et al.
Published: (2021-10-01)

Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer
by: LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao
Published: (2022-05-01)

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
by: Chaokun Wang MS, et al.
Published: (2020-09-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
by: Nicola Cosgrove, et al.
Published: (2023-09-01)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
by: Gavin P. Dowling, et al.
Published: (2023-01-01)

Current neoadjuvant treatment options for HER2 positive breast cancer
by: Abdel-Razeq H, et al.
Published: (2011-08-01)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01)

<i>FGFR1</i> Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
by: María Gaibar, et al.
Published: (2022-01-01)

Technologies and innovation for improving performances logistic operators: the Techlog project
by: Gianfranco Fancello
Published: (2022-06-01)

“Just give her a banana”: An ethnographic exploration of causes of stunting in Aceh, Indonesia
by: Nouval Ramadhan, et al.
Published: (2023-06-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: a case-control study in a population from North Sardinia
by: Matteo Floris, et al.
Published: (2020-03-01)

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
by: M. C. Liefaard, et al.
Published: (2024-04-01)

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
by: Zheng-Jun Yang, et al.
Published: (2024-01-01)

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
by: Shuling Zhou, et al.
Published: (2023-02-01)